COO vs EW

For growth investors, Edwards Lifesciences Corporation (EW) is the stronger pick with 11.

5% revenue growth year-over-year, versus 5. 1% for The Cooper Companies, Inc. (COO). The Cooper Companies, Inc. (COO) offers the better valuation at 32. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate The Cooper Companies, Inc. (COO) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Cooper Companies, Inc.

(COO) is the cheapest at 32. 7x versus Edwards Lifesciences Corporation at 45. 5x. On forward P/E, The Cooper Companies, Inc. is actually cheaper at 13. 2x.

Over the past 5 years, Edwards Lifesciences Corporation (EW) delivered a total return of -9.

3%, compared to -39. 7% for The Cooper Companies, Inc. (COO). Over 10 years, the gap is even starker: EW returned +136. 1% versus COO's +59. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edwards Lifesciences Corporation (EW) is the lower-risk stock at 0.

65β versus The Cooper Companies, Inc. 's 0. 93β — meaning COO is approximately 43% more volatile than EW relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 34% for The Cooper Companies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Edwards Lifesciences Corporation (EW) is pulling ahead at 11.

5% versus 5. 1% for The Cooper Companies, Inc. (COO). On earnings-per-share growth, the picture is similar: The Cooper Companies, Inc. grew EPS -4. 6% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, COO leads at 7. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus 9. 2% for The Cooper Companies, Inc. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus 16. 7% for COO. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Cooper Companies, Inc.

(COO) trades at 13. 2x forward P/E versus 27. 7x for Edwards Lifesciences Corporation — 14. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COO: 53. 6% to $93. 86.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Edwards Lifesciences Corporation (EW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), +136. 1% 10Y return). Both have compounded well over 10 years (EW: +136. 1%, COO: +59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.